trending Market Intelligence /marketintelligence/en/news-insights/trending/OQmqEhwG-yUyVqh1Ulqttw2 content esgSubNav
In This List

Cerulean exploring strategic alternatives

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Cerulean exploring strategic alternatives

Cerulean Pharma Inc.'s board is conducting a comprehensive review of strategic options to maximize shareholder value.

The review is to evaluate potential alternatives such as the sale of the company; a merger; a business combination; a strategic investment in the company; or a sale, license or disposition of its assets.

Also in the review, the board is considering certain clinical assets, the company's nanoparticle-drug conjugates platform and cash reserves.